You are here: Industry Insights > Amplyx

News List

Arix Bioscience plc: Team changes firstwordpharma
July 07, 2021
Arix Bioscience plc (“Arix” or “the Company”) (LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Mark Chin will be re-joining the Arix investment team as a Managing Director
Pfizer Acquires Amplyx Pharmaceuticals contractpharma
April 30, 2021
Pfizer has acquired Amplyx Pharmaceuticals, a privately-held company dedicated to the development of therapies for immune system disorders.
Amplyx Announces Positive Top-line Data in Antifungal Fosmanogepix Trial americanpharmaceuticalreview
July 27, 2020
Amplyx Pharmaceuticals announced positive topline data following the completion of its Phase 2 clinical trial of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida.
Fast Track designation granted to fosmanogepix for seven indications europeanpharmaceuticalreview
September 12, 2019
Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.
FDA Grants Fast Track to Amplyx for IV and Oral Formulations of Fosmanogepix americanpharmaceuticalreview
September 10, 2019
Amplyx Pharmaceuticals announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antifungal candidate...
FDA Grants Orphan Drug Designation to Amplyx for APX001 for Cryptococcosis Treatment americanpharmaceuticalreview
February 13, 2019
Amplyx Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001 ....